| 周秀珍,张丽娜,申 静,金晓琳,范国锋.脑胶质瘤患者血清VTN、IGFBP、UBE2C水平与临床病理特征和预后的关系研究[J].,2022,(4):693-697 |
| 脑胶质瘤患者血清VTN、IGFBP、UBE2C水平与临床病理特征和预后的关系研究 |
| Study on the Relationship between Serum VTN, IGFBP, UBE2C Levels and Clinicopathological Characteristics and Prognosis in Patients with Brain Glioma |
| 投稿时间：2021-06-05 修订日期：2021-06-29 |
| DOI：10.13241/j.cnki.pmb.2022.04.020 |
| 中文关键词: 脑胶质瘤 预后 玻连蛋白 类胰岛素样生长因子结合蛋白 泛素耦联酶2C 病理特征 |
| 英文关键词: Brain glioma Prognosis Hyalonectin Insulin-like growth factor binding protein Ubiquitin coupled enzyme 2C Pathological characteristics |
| 基金项目:新疆维吾尔自治区自然科学基金项目（2016D01C326） |
|
| 摘要点击次数: 585 |
| 全文下载次数: 279 |
| 中文摘要: |
| 摘要 目的：研究脑胶质瘤患者血清玻连蛋白（VTN）、类胰岛素样生长因子结合蛋白（IGFBP）、泛素耦联酶2C（UBE2C）水平与临床病理特征和预后的关系。方法：将新疆医科大学第一附属医院从2019年1月～2020年1月收治的97例脑胶质瘤患者纳入研究，记作研究组，另取同期于本院进行体检的健康志愿者90例作为对照组。此外，对所有研究组人员均进行为期1年的随访，将其按照随访结局的差异分作死亡组40例和存活组57例。检测并比较各组血清VTN、IGFBP、UBE2C水平，分析血清VTN、IGFBP、UBE2C水平与脑胶质瘤患者临床病理特征和预后的关系，并以受试者工作特征（ROC）曲线分析血清VTN、IGFBP、UBE2C水平预测脑胶质瘤患者死亡的效能。结果：研究组血清VTN、IGFBP及UBE2C水平均高于对照组（均P＜0.05）。肿瘤大小≥5 cm、世界卫生组织（WHO）分级为Ⅲ～Ⅳ级、Karnofsky功能状态（KPS）＜70分脑胶质瘤患者的血清VTN、IGFBP水平均高于肿瘤大小＜5 cm、WHO分级为Ⅰ～Ⅱ级、KPS评分≥70分的脑胶质瘤患者（均P＜0.05）；WHO分级为Ⅲ～Ⅳ级、KPS评分＜70分脑胶质瘤患者的血清UBE2C水平高于WHO分级为Ⅰ～Ⅱ级、KPS评分≥70分的脑胶质瘤患者（均P＜0.05）。死亡组血清VTN、IGFBP、UBE2C水平均高于存活组（均P＜0.05）。经ROC曲线分析发现：血清VTN、IGFBP、UBE2C水平联合检测预测脑胶质瘤患者死亡的曲线下面积、灵敏度、特异度及约登指数均高于上述三项指标单独检测。结论：脑胶质瘤患者血清VTN、IGFBP、UBE2C水平均存在异常高表达，且与肿瘤恶性进展相关，联合检测可能有利于预测患者的预后。 |
| 英文摘要: |
| ABSTRACT Objective: To study the relationship between serum hyalonectin (VTN), insulin-like growth factor binding protein (IGFBP), ubiquitin-coupled enzyme 2C (UBE2C) levels and clinicopathological characteristics and prognosis in patients with brain glioma. Methods: A total of 97 patients with glioma admitted to the first affiliated hospital of Xinjiang medical university from January 2019 to January 2020 were included as the study group, and 90 healthy volunteers who underwent physical examination in the hospital during the same period were included as the control group. In addition, all the study group researchers were followed up for 1 year, and they were divided into the death group (40 cases) and the survival group (57 cases) according to the difference in follow-up outcomes. Serum VTN, IGFBP and UBE2C levels were detected and compared in each group, and the relationship between serum VTN, IGFBP and UBE2C levels and clinicopathological features and prognosis of glioma patients was analyzed. The efficacy of serum VTN, IGFBP and UBE2C levels in predicting the death of glioma patients was analyzed by receiver operating characteristic (ROC) curve. Results: The serum VTN, IGFBP and UBE2C levels in the study group were higher than those in the control group (all P<0.05). Serum VTN and IGFBP levels in patients with brain glioma with tumor size ≥5 cm, world health organization（WHO） classification Ⅲ ~ Ⅳ grade and Karnofsky functional status (KPS) score < 70 scores were higher than those in patients with brain glioma with tumor size < 5 cm, WHO classification Ⅰ～Ⅱ grade and KPS score ≥70 scores (all P<0.05). The serum UBE2C level of patients with brain glioma with WHO classification Ⅲ～Ⅳ grade and KPS score < 70 scores were higher than that of patients with brain glioma with WHO classification Ⅰ～Ⅱ grade and KPS score ≥70 scores (all P<0.05). Serum VTN, IGFBP and UBE2C levels in the death group were higher than those in the survival group (all P<0.05). ROC curve analysis showed that the area under the curve, sensitivity, specificity and Youden index of the combined detection of serum VTN, IGFBP and UBE2C levels in predicting the death of patients with brain glioma were all higher than those of the above three indexes alone. Conclusion: There are abnormally high levels of SERUM VTN, IGFBP and UBE2C in glioma patients, which are related to the progression of tumor malignancies. Combined detection may be beneficial to predict the prognosis of patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
